SPRYD7 and melanoma: Even if the fusions themselves are most likely not biologically active, MTAP-ANRIL has been detected in melanoma patients in association with the deletion of the tumor suppressor genes CDKN2A/B [31], RCBTB2-LPAR6 indicates a partial RB1 loss as part of a larger deletion [32], and DLEU2-SPRYD7 indicates the deletion of the miR-15a/16–1 cluster (Fig. 2).